EyePoint Pharmaceuticals

Press Releases

EyePoint Pharmaceuticals Provides Business Update and Preliminary Fourth Quarter and Full-Year 2020 Net Product Revenues
Jan 11, 2021
- IND filed in December 2020 for EYP-1901, a potential six-month sustained delivery intravitreal  anti-VEGF treatment targeting wet age-related macular degeneration - - Anticipated Phase 1 clinical trial initiation in Q1 2021 - - Q4 2020 net product revenues are estimated to be $6.2 - $6.6
EyePoint Pharmaceuticals Announces $15.7 Million Equity Investment by Asia Partner Ocumension Therapeutics
Jan 03, 2021
WATERTOWN, Mass. , Jan. 03, 2021 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals , Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced that Ocumension Therapeutics , a China -based ophthalmic pharmaceutical company
EyePoint Pharmaceuticals Announces $16.5 Million Monetization of ILUVIEN® Royalty with SWK Holdings Corporation
Dec 18, 2020
WATERTOWN, Mass. , Dec. 18, 2020 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals , Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing innovative therapeutics to help improve the lives of patients with serious eye disorders, today announced a royalty monetization
EyePoint Pharmaceuticals Announces 1-for-10 Reverse Stock Split
Dec 08, 2020
WATERTOWN, Mass. , Dec. 08, 2020 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals , Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced that it will effect a 1-for-10 reverse stock split at 5:00 p.m.
EyePoint Pharmaceuticals Reports Positive Results from GLP Toxicology Study of EYP-1901, a Potential Six-month Treatment of Wet Age-related Macular Degeneration
Dec 03, 2020
- No unexpected safety findings during the course of the study - -   On track to file an IND by end of year; Phase 1 clinical trial to commence in early 2021 - WATERTOWN, Mass. , Dec. 03, 2020 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals , Inc. (NASDAQ: EYPT), a pharmaceutical company committed to
EyePoint Pharmaceuticals to Host Key Opinion Leader Virtual Roundtable on the Future of Drug Delivery for Wet AMD on December 4
Nov 19, 2020
WATERTOWN, Mass. , Nov. 19, 2020 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals , Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced it will host a key opinion leader roundtable discussion on the future of local
EyePoint Pharmaceuticals Presents Positive Data of YUTIQ® and DEXYCU® in Four Poster Sessions at the American Academy of Ophthalmology 2020 Virtual Annual Meeting
Nov 16, 2020
-   Second Phase 3 trial of YUTIQ   confirms 36-month   positive efficacy   results from the first Phase 3 trial - -   Study of DEXYCU vs. Prednisolone e ye d rops shows high patient preference for D EXYCU regimen with statistically better inflammation control, pain, visual acuity outcomes in D
EyePoint Pharmaceuticals Announces Presentations at the Upcoming American Academy of Ophthalmology 2020 Virtual Annual Meeting
Nov 10, 2020
WATERTOWN, Mass. , Nov. 10, 2020 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals , Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced that four abstracts featuring YUTIQ® and DEXYCU® have been selected for
EyePoint Pharmaceuticals Reports Third Quarter 2020 Financial Results and Highlights Recent Corporate Developments
Nov 05, 2020
- Total revenues of $ 15.7 million and net product revenues of $ 5. 8 million - -   S equential quarterly increase in underlying customer demand of   over 12 0 % for DEXYCU ® and over 5% for YUTIQ®   - - EYP-1901, a potential six-month sustained delivery   intravitreal anti-VEGF treatment targeting
EyePoint Pharmaceuticals Announces Third Quarter 2020 Financial Results Release Date and Conference Call Information
Oct 29, 2020
WATERTOWN, Mass. , Oct. 29, 2020 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals , Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing innovative ophthalmic products, will report results for its third quarter 2020 on Thursday, November 5, 2020 .
EyePoint Pharmaceuticals Announces Amendment to CRG Debt Facility Modifying 2020 and 2021 Revenue Covenants
Oct 08, 2020
WATERTOWN, Mass. , Oct. 08, 2020 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals , Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced an amendment to its existing debt facility with CRG Servicing LLC (CRG).
EyePoint Pharmaceuticals Announces Preliminary Net Product Revenue for Third Quarter 2020
Oct 07, 2020
- Q 3 20 20 net product revenues are estimated to be between $ 5.5   - $ 5.9   million, as   healthcare facilities began reopening from COVID-19 closures - - Sequential increase in underlying customer demand for both YUTIQ and DEXYCU from Q2 2020 WATERTOWN, Mass. , Oct.
EyePoint Pharmaceuticals Announces Participation at Upcoming Investor Conferences
Sep 10, 2020
WATERTOWN, Mass. , Sept. 10, 2020 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a pharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced that Nancy Lurker , President and Chief Executive Officer, will present in two
EyePoint Pharmaceuticals Secures New Purchase and Marketing Agreement with Vantage Outsourcing for DEXYCU®
Aug 24, 2020
WATERTOWN, Mass. , Aug. 24, 2020 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals , Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced that it has entered into a purchase and marketing agreement with Vantage
EyePoint Pharmaceuticals Receives $9.5 Million in Upfront Cash from Ocumension Therapeutics Under Expanded License Agreements
Aug 20, 2020
WATERTOWN, Mass. , Aug. 20, 2020 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals , Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing innovative ophthalmic products, and Ocumension Therapeutics, a China -based ophthalmic pharmaceutical platform company, today
EyePoint Pharmaceuticals Reports Second Quarter 2020 Financial Results and Highlights Recent Corporate Developments
Aug 05, 2020
- Total revenues of $4.1 million and net product revenues of $3.7 million impacted by COVID-19 pandemic - - U.S. commercial alliance with ImprimisRx to expand reach of DEXYCU® - - Jay S. Duker , M.D., world-renowned retinal specialist, joins as Chief Strategic Scientific Officer to lead EYP-1901
EyePoint Pharmaceuticals and Harrow Health’s ImprimisRx Announce U.S. Commercial Alliance for DEXYCU®
Aug 04, 2020
- Collaboration to bring DEXYCU to ImprimisRx’s established customer base of ophthalmologists, hospitals, and ambulatory surgical centers - WATERTOWN, Mass. and NASHVILLE, Tenn. , Aug. 04, 2020 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals , Inc. (NASDAQ: EYPT), a pharmaceutical company committed to
EyePoint Pharmaceuticals Announces Second Quarter 2020 Financial Results Release Date and Conference Call Information
Jul 29, 2020
WATERTOWN, Mass. , July 29, 2020 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals , Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing innovative ophthalmic products, will report results for its second quarter 2020 on Wednesday, August 5, 2020 .
EyePoint Pharmaceuticals Presents Data Supporting YUTIQ® at the American Society of Retina Specialists (ASRS) Virtual Annual Meeting
Jul 27, 2020
WATERTOWN, Mass. , July 27, 2020 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals , Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced the presentation of data supporting YUTIQ® (fluocinolone acetonide intravitreal
EyePoint Pharmaceuticals Expands Executive Leadership Team with the Appointment of Jay S. Duker, M.D., as Chief Strategic Scientific Officer
Jul 13, 2020
- World-renowned retina specialist to lead EYP-1901 development efforts and support expansion of EyePoint’s ocular disease pipeline - WATERTOWN, Mass. , July 13, 2020 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals , Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and
Displaying 1 - 20 of 396
EyePoint Pharmaceuticals